Procedure partially blocks blood flow to the gland and appears to ease the need to urinate.
Overall, men with LUTS showed remarkably poor knowledge about their symptoms.
In a study, severe nocturia predicted increased mortality risk.
Increasing secretion of this hormone may prevent and treat the condition.
Keeping abreast of the most current treatments for idiopathic OAB can lead to improved outcomes and quality of life.
Two studies show significant reduction in number of nocturnal voids for women.
The prevalence and severity of nocturia, or awakening at least once at night to urinate, tends to increase with age.
Moderate nocturia may increase the risk of death among men aged 60 years and older, according to study. Among younger men, it may increase the likelihood of developing coronary heart disease later in life.
In an update to its 2004 guidance on screening for bladder cancer, the United States Preventive Services Task Force (USPSTF) has changed its recommendation from a D (lack of evidence) to an I (insufficient evidence) statement, finding inadequate data to support disease screening for asymptomatic adults or for adults with mild lower urinary tract symptoms such as urinary frequency, hesitancy, urgency, dysuria, or nocturia.
GLASGOW—Bedwetting in childhood is a strong indicator of persisting enuresis in adulthood, researchers concluded in a report presented here at the International Continence Society annual meeting.
WASHINGTON, D.C.—Nocturia is the most common overactive bladder (OAB) symptom affecting health-related quality of life (HRQL) in patients with postural tachycardia syndrome (POTS), investigators reported at the American Urological Association 2011 annual meeting.
SAN FRANCISCO—Nocturia, defined as two or more urinations per night, is associated with an increased risk of death, even after adjusting for comorbidities known to increase mortality, according to two new studies presented at the American Urological Association annual meeting.
Vantia Therapeutics, a British pharmaceutical company, has begun a Phase 2b trial of its lead development compound VA106483 for nocturia, according to a company statement.
Researchers have identified four new independent risk factors for the development of end-stage renal disease (ESRD). These are higher serum uric acid levels, lower hemoglobin levels, family history of kidney disease, and self-reported history of nocturia.
Celecoxib is effective for treating BPH patients with refractory nocturia, researchers in Iran reported in Urology (2008; online ahead of print).
Irritative lower urinary tract symptoms (LUTS) and nocturia are positively associated with diabetes, a study found. The relationship is greater in black than white men.
Renal and Urology News Articles
- Mediterranean Diet Best for Lowering Aggressive Prostate Cancer Risk
- SABR for Renal Cell Carcinoma Offers Excellent Outcomes
- Radical Cystectomy Offers Better Long-term MIBC Patient Survival
- Robotic Kidney Transplantation Safe, Feasible
- Most CKD Patients With Anemia Show Limited Response to Oral Iron
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)